Biopharmaceutical company Oculis Holding AG will host an in-person R&D Day in midtown New York City from 9 to 11 am February 28. The event will provide development updates on two of Oculis’s clinical programs, OCS-01 and OCS-02.

OCS-01 is a high-concentration dexamethasone eye drop formulation being developed to treat diabetic macular edema (DME) as well as inflammation and pain following cataract surgery. OCS-01 uses the company’s proprietary Optireach technology to access the retina. Presentations will include a discussion of how OCS-01 could transform the treatment paradigm with David Boyer, MD; Arshad M. Khanani, MD, MA, FASRS; EURETINA President Ramin Tadayoni, MD, PhD; and ASCRS President Elizabeth Yeu, MD.

OCS-02, a TNFα inhibitor licaminlimab eye drop formulation developed with a proprietary antibody fragment technology to treat ocular inflammation in dry eye disease (DED). Presenters including Christophe Baudouin, MD, PhD; Eric Donnenfeld, MD; Anat Galor, MD, MSPH; George Ousler, MS; and Victor Perez, MD will discuss how TNFα inhibitors can manage ocular inflammation, the potential for a precision medicine approach in DED, and an overview of the licaminlimab (OCS-02) RELIEF trial program.

To register for either the in-person or virtual event, click here